{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T03:55:44Z","timestamp":1775102144758,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,11]],"date-time":"2023-02-11T00:00:00Z","timestamp":1676073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,11]],"date-time":"2023-02-11T00:00:00Z","timestamp":1676073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Universit\u00e4tsklinik M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The progressive course of pulmonary fibrosis (PPF) is observed with variable prevalence in different entities of fibrosing interstitial lung disease (fILD). PPF is characterised by worsening respiratory symptoms, declining lung function and increasing extent of fibrosis on high-resolution computer tomography. In Germany, data are limited on the characteristics and management of such patients.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods\/Design<\/jats:title>\n                <jats:p>INSIGHTS-ILD is a prospective observational longitudinal registry designed to describe characteristics, management and course of newly diagnosed (incident) and prevalent patients with fILD on the long term. The registry uses a non-probability sampling approach to collect data on characteristics, therapeutic interventions, health-related quality of life and health economic parameters. It is planned to include 900 patients in ambulatory care in about 30 expert sites over three years. The study has been initiated in December 2021, and currently (January 2023) follows 360 patients.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>The registry is expected to provide much-needed data on the characteristics, management, and trajectories of patients fILD in Germany. The start of the study comes at a time when new treatment options are available for PPF. We hypothesize that PPF represents a broad clinical phenotype that is differentially influenced by inflammatory and fibrotic pathomechanisms that need to be treated with anti-inflammatory and\/or anti-fibrotic treatment strategies. This registry will allow comparisons with other countries. Gap analyses based on current guidelines for management of these patients will be possible.<\/jats:p>\n                <jats:p><jats:italic>Trial registration<\/jats:italic> DRKS00027389 (registered on 7.12.2021), BfArM NIS 7562.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12890-023-02333-7","type":"journal-article","created":{"date-parts":[[2023,2,11]],"date-time":"2023-02-11T13:03:52Z","timestamp":1676120632000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Investigating significant health trends in progressive fibrosing interstitial lung disease (INSIGHTS-ILD): rationale, aims and design of a nationwide prospective registry"],"prefix":"10.1186","volume":"23","author":[{"given":"Juergen","family":"Behr","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Bonella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"G\u00fcnther","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Koschel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antje","family":"Prasse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Pittrow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Klotsche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Kreuter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"INSIGHTS-ILD Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioana","family":"Andreica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen","family":"Behr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heike","family":"Biller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Claussen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Budweiser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Eisenmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralf","family":"Ewert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Gesierich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sven","family":"Gl\u00e4ser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Groh\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Grund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Achim","family":"Gr\u00fcnewaldt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"Hagmeyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Held","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans-Joachim","family":"Kabitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joachim","family":"Kirschner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Markart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"Neff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claus","family":"Neurohr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Reichenberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Schramm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Schwaiblmair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernd","family":"Seese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Skowasch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"W\u00e4lscher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Weber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Westhoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heinrike","family":"Wilkens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hubert","family":"Wirtz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,2,11]]},"reference":[{"issue":"6","key":"2333_CR1","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","volume":"188","author":"WD Travis","year":"2013","unstructured":"Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG, et al. An official American Thoracic Society\/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188(6):733\u201348.","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"2333_CR2","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/S2213-2600(20)30355-6","volume":"8","author":"PM George","year":"2020","unstructured":"George PM, Spagnolo P, Kreuter M, Altinisik G, Bonifazi M, Martinez FJ, et al. Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities. Lancet Respir Med. 2020;8(9):925\u201334.","journal-title":"Lancet Respir Med"},{"issue":"150","key":"2333_CR3","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0076-2018","volume":"27","author":"V Cottin","year":"2018","unstructured":"Cottin V, Hirani NA, Hotchkin DL, Nambiar AM, Ogura T, Otaola M, et al. Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases. Eur Respir Rev. 2018;27(150): 180076.","journal-title":"Eur Respir Rev"},{"issue":"9","key":"2333_CR4","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","volume":"205","author":"G Raghu","year":"2022","unstructured":"Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T, et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2022;205(9):e18\u201347.","journal-title":"Am J Respir Crit Care Med"},{"key":"2333_CR5","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1097\/MCP.0000000000000805","volume":"27","author":"AU Wells","year":"2021","unstructured":"Wells AU, Brown KK, Cottin V. The progressive fibrotic phenotype in current clinical practice. Curr Opin Pulmon Med. 2021;27:368\u201373.","journal-title":"Curr Opin Pulmon Med"},{"issue":"1","key":"2333_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2017-000212","volume":"4","author":"KR Flaherty","year":"2017","unstructured":"Flaherty KR, Brown KK, Wells AU, Clerisme-Beaty E, Collard HR, Cottin V, et al. Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease. BMJ Open Respir Res. 2017;4(1): e000212.","journal-title":"BMJ Open Respir Res"},{"issue":"Suppl 5","key":"2333_CR7","first-page":"v1","volume":"63","author":"B Bradley","year":"2008","unstructured":"Bradley B, Branley HM, Egan JJ, Greaves MS, Hansell DM, Harrison NK, et al. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax. 2008;63(Suppl 5):v1-58.","journal-title":"Thorax"},{"issue":"3","key":"2333_CR8","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1136\/thx.2004.031062","volume":"63","author":"JW Wilson","year":"2008","unstructured":"Wilson JW, du Bois RM, King TE Jr. Challenges in pulmonary fibrosis: 8\u2013The need for an international registry for idiopathic pulmonary fibrosis. Thorax. 2008;63(3):285\u20137.","journal-title":"Thorax"},{"issue":"9","key":"2333_CR9","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1136\/thx.2008.100222","volume":"63","author":"A Guenther","year":"2008","unstructured":"Guenther A, Eickelberg O, Preissner KT, Chambers R, Laurent G, Wells A, et al. International registry for idiopathic pulmonary fibrosis. Thorax. 2008;63(9):841 (author reply).","journal-title":"Thorax"},{"issue":"1","key":"2333_CR10","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1183\/09031936.00217614","volume":"46","author":"J Behr","year":"2015","unstructured":"Behr J, Kreuter M, Hoeper MM, Wirtz H, Klotsche J, Koschel D, et al. Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry. Eur Respir J. 2015;46(1):186\u201396.","journal-title":"Eur Respir J"},{"issue":"1","key":"2333_CR11","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s12931-017-0621-y","volume":"18","author":"M Kreuter","year":"2017","unstructured":"Kreuter M, Swigris J, Pittrow D, Geier S, Klotsche J, Prasse A, et al. Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: insights-IPF registry. Respir Res. 2017;18(1):139.","journal-title":"Respir Res"},{"issue":"2","key":"2333_CR12","doi-asserted-by":"publisher","first-page":"1902279","DOI":"10.1183\/13993003.02279-2019","volume":"56","author":"J Behr","year":"2020","unstructured":"Behr J, Prasse A, Wirtz H, Koschel D, Pittrow D, Held M, et al. Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry. Eur Resp J. 2020;56(2):1902279.","journal-title":"Eur Resp J"},{"issue":"13","key":"2333_CR13","doi-asserted-by":"publisher","DOI":"10.1055\/s-0031-1271828","volume":"136","author":"U Glatz","year":"2011","unstructured":"Glatz U. GOLDnet\u2014focus on rare lung diseases. Dtsch Med Wochenschr. 2011;136(13): p10.","journal-title":"Dtsch Med Wochenschr"},{"key":"2333_CR14","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/123876","volume":"2015","author":"M Kreuter","year":"2015","unstructured":"Kreuter M, Herth FJ, Wacker M, Leidl R, Hellmann A, Pfeifer M, et al. Exploring clinical and epidemiological characteristics of interstitial lung diseases: rationale, aims, and design of a nationwide prospective registry\u2014The EXCITING-ILD Registry. Biomed Res Int. 2015;2015: 123876.","journal-title":"Biomed Res Int"},{"key":"2333_CR15","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1164\/rccm.201604-0801CI","volume":"194","author":"HR Collard","year":"2016","unstructured":"Collard HR, Ryerson CJ, Corte TJ, Jenkins G, Kondoh Y, Lederer DJ, et al. Acute exacerbation of idiopathic pulmonary fibrosis: an international working group report. Am J Respir Crit Care Med. 2016;194:266\u201375.","journal-title":"Am J Respir Crit Care Med"},{"key":"2333_CR16","unstructured":"Deutsche Gesellschaft f\u00fcr Epidemiologie (GGEpi). Leitlinien und Empfehlungen zur Sicherung von Guter Epidemiologischer Praxis (GEP). Aktualisierung September 2018. https:\/\/www.dgepi.de\/assets\/Leitlinien-und-Empfehlungen\/Leitlinien_fuer_Gute_Epidemiologische_Praxis_GEP_vom_September_2018.pdf. Zugriff am 4. Jan 2021"},{"key":"2333_CR17","unstructured":"Agency for Healthcare Research and Quality (AHRQ). Registries for Evaluating Patient Outcomes: A User's Guide. Senior Editors: RE Gliklich, MB Leavy, NA Dreyer. AHRQ Publication No.19(29)-EHC020. Rockville, MD, USA. Forth edition 2020. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK562575\/. Accessed 4 Jan 2021."},{"issue":"1","key":"2333_CR18","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1136\/ebmed-2017-110885","volume":"23","author":"IJ Onakpoya","year":"2018","unstructured":"Onakpoya IJ. Rare adverse events in clinical trials: understanding the rule of three. BMJ Evid Based Med. 2018;23(1):6.","journal-title":"BMJ Evid Based Med"},{"issue":"7005","key":"2333_CR19","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1136\/bmj.311.7005.619","volume":"311","author":"E Eypasch","year":"1995","unstructured":"Eypasch E, Lefering R, Kum CK, Troidl H. Probability of adverse events that have not yet occurred: a statistical reminder. BMJ. 1995;311(7005):619\u201320.","journal-title":"BMJ"},{"key":"2333_CR20","unstructured":"International Federation of Pharmaceutical Manufacturers and Associations (IFPMA). MedDRA (Medical Dictionary for Regulatory Activities). https:\/\/www.meddra.org\/mssoweb\/index.htm. Accessed 04 Jan 2021."},{"issue":"7624","key":"2333_CR21","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","volume":"335","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007;335(7624):806\u20138.","journal-title":"BMJ"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-023-02333-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-023-02333-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-023-02333-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T13:05:30Z","timestamp":1676293530000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-023-02333-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,11]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2333"],"URL":"https:\/\/doi.org\/10.1186\/s12890-023-02333-7","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,11]]},"assertion":[{"value":"1 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The registry materials (protocol, patient information and informed consent form (ICF), and other required documents) were approved by the primary ethics committee (Ethics Committee of the Physician Chamber Saxony EK-BR-125\/21-1 dated 1. December 2021). Any site that joins the registry has to provide additional ethics approval, if required by their local institutions. Protocol amendments, if any, will be subject to the same requirements as the original protocol. Written informed consent is a prerequisite for patients to be eligible for documentation in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. The manuscript does not contain any individual person\u2019s data in any form.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JB: J\u00fcrgen Behr received honoraria for consulting and lectures from Actelion, Astra-Zeneca, Biogen, BMS, Boehringer-Ingelheim, Ferrer, Galapagos, Novartis, Roche, Sanofi-Genzyme. The INSIGHTS-ILD study is funded by Boehringer Ingelheim, Germany. FB: grants to his institution by Boehringer Ingelheim and Roche, fees for consulting by Savara, Roche, Sanofi and Boehringer Ingelheim. DP: received consultancy fees from Amgen, Aspen, Biogen, Daiichi Sankyo, Sanofi-Genzyme, Sandoz\/Novartis and MSD. AP: none. JK: none. DK: fees for consulting by Roche and Boehringer Ingelheim. MK: grants to his institution by Boehringer Ingelheim and Roche, fees for consulting by Roche, Galapagos and Boehringer Ingelheim.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"64"}}